Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Koygo Co., Ltd.

Shigeto Kitamura

Fumio Suzuki

Shunji Ichikawa

Takeshi Kuroda

Hiroshi Kase

Isao Kawamoto

Junichi Shimada

Joji Nakamura

Nobuaki Koike

Kenji Shibata

Motoo Yamasaki

Keiichi Yano

Kazuo Yamaguchi

Eiji Tsukuda

Kenji Ohmori

Yuzuru Matsuda

Toshiyuki Suzawa

Shigeru Chiba

Mayumi Yoshida

Takeo Tanaka

Tatsuhiro Ogawa

Yoshikazu Morishita

Chieko Bando

Mika Makino

Toshihide Ikemura

Katsuichi Shuto

Shizuo Shiozaki

Takao Iida

Haruhiko Manabe

Kenji Omori

Hiroshi Sano

Mitsuru Takahashi

Koji Yamada

Chikara Murakata

Masaji Kasai

Kunikatsu Shirahata

Hiromitsu Saito

Akio Ishii

Hiromi Nonaka

Toshiaki Kumazawa

Masayuki Teranishi

Tomoyuki Kanda

Yoshikazu Miwa

Koji Suzuki

Takashi Kawakita

Shigeru Aono

Kazuko Hashizume

Hirokazu Koshimura

Endothelin-antagonizing peptide

The invention relates to biologically pure cultures of Streptomyces sp. RE-701 (FERM BP-3624) and Streptomyces sp. RE-629 (FERM BP-4126) that produce endothelin antagonistic peptides.

Strains of streptomyces producing endothelin antagonistic peptides

Phenylpiperidine derivative

Method of treating depression with certain triazine derivatives

Xanthine derivatives

Peptides represented by the following formula (I): ##STR1## wherein A represents Asn or Asp; B represents His or Lys; and E represents Ala or Ser;

Therapeutic purine agents for parkinson's disease

Antidepressants

Disclosed are imidazonaphthyridine derivatives represented by formula (I) ##STR1## wherein: R.sup.1 represents lower alkyl or substituted or unsubstituted aryl; and

Imidazonaphthyridine derivatives

Thienoimidazoppyridone derivatives

A hydroxamic acid compound represented by the general formula (I) or a salt thereof; ##STR1## wherein R.sup.1 represents a hydrogen atom, or a substituted or unsubstituted alkanoyl group, R.sup.2 represents an unsubstituted alkanoyl, substituted lower alkanoyl or substituted lower alkyl group, and m represents an integer of 3 to 7, which are useful for the prevention and/or treatment of diseases caused by lipoxygenase-mediated metablites.

Hydroxamic acid derivatives and use thereof in combatting

A quinoline-N-oxide derivative represented by the formula: ##STR1## wherein X is hydroxy, lower alkoxy, lower alkylthio, unsubstituted or substituted aralkyloxy, or unsubstituted or substituted aralkylthio; Y is a hydrogen atom or halogen atom; R.sub.1 is alkylene or alkenylene having 3 to 15 carbon atom; Z is hydroxymethyl, lower alkoxymethyl, unsubstituted or substituted aryloxymethyl, tetrahydropyranyloxymethyl, tetrahydrofuranyloxymethyl, unsubstituted or substituted arylsulfonyloxymethyl, lower alkylthiomethyl, unsubstituted or substituted arylthiomethyl, lower alkylsulfinylmethyl, unsubstituted or substituted arylsulfinylmethyl, lower alkylsulfonylmethyl, unsubstituted or substituted arylsulfonylmethyl, aminomethyl, --CH.sub.2 NHR.sub.2 (wherein R.sub.2 is lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), --CH.sub.2 NR.sub.3 R.sub.4 (wherein R.sub.3 and R.sub.4 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl), --CH.sub.2 N.sup.+ R.sub.5 R.sub.6 R.sub.7 (wherein R.sub.5, R.sub.6, and R.sub.7 are lower alkyl, unsubstituted or substituted aralkyl, or unsubstituted or substituted aryl, where the counterion is an anion of acid or a hydroxyl ion), --COR.sub.8 (wherein R.sub.8 is a hydrogen atom, lower alkyl or hydroxy), --CH(OR.sub.9).sub.2 (wherein R.sub.9 is lower alkyl), iminomethyl, hydroxyiminomethyl, or a halogen atom and its salts, can very strongly inhibit the lipoxygenase and considerably suppress production and release of its metabolites, and thus are useful as preventive and healing agents for the diseases caused by the lipoxygenase metabolites.

Quinoline-N-oxide derivative and pharmaceutical composition

Growing community of inventors

Machida, Japan

Shigeto Kitamura